Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05829655 · ClinicalTrials.gov registry record · Early Phase 1
Measuring Acute Drug Demand in Humans
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 75
- Enrollment target
NCT05829655: Recruiting Early Phase 1 study, sponsored by University of Maryland, Baltimore.
NCT05829655 is a Early Phase 1 study that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 75 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05829655, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
Primary Outcome
Consumption of blinded drug at unconstrained price as measured by an incentivized demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more drug consumption at unconstrained price (a worse outcome).
Interventions
- DRUG Drug A (Blinded Drug)
- DRUG Drug B (Blinded Drug)
- DRUG Drug C (Blinded Drug)
- DRUG Drug D (Blinded Drug)
- DRUG Suvorexant (20mg/day)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
What NCT05829655 shows while recruiting
NCT05829655 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 5 interventions - of which Drug A (Blinded Drug) is the first listed.
NCT05829655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05829655 about?
NCT05829655 is a clinical study titled "Measuring Acute Drug Demand in Humans". This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
What is the current status of trial NCT05829655?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2023-08-08. Estimated completion is 2028-01-01.
What interventions are being tested in trial NCT05829655?
The interventions under investigation include: Drug A (Blinded Drug) (DRUG), Drug B (Blinded Drug) (DRUG), Drug C (Blinded Drug) (DRUG), Drug D (Blinded Drug) (DRUG), Suvorexant (20mg/day) (DRUG).
Who is sponsoring clinical trial NCT05829655?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05829655's enrollment target sits among peer trials
75 304th of 2000 higher than 1,690 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI